Genefit (GNFTF) 39.0800 $GNFTF
GENFIT : THERAPEUTIC POTENTIAL OF GFT505 WIDENED TO NON-HEPATIC FIBROTIC DISEASES; NEW INSIGHTS ON ITS ANTI-FIBROTIC MECHANISM OF ACTION
Thomson Reuters ONE - Mon Apr 14, 1:30AM CDT
GENFIT: THERAPEUTIC POTENTIAL OF GFT505 WIDENED TO NON-HEPATIC FIBROTIC DISEASES; NEW INSIGHTS ON ITS ANTI-FIBROTIC MECHANISM OF ACTION
GENFIT: ORGANIZATION OF A WORKSHOP ON GFT505 DURING THE ANNUAL EASL CONGRESS
Thomson Reuters ONE - Tue Apr 08, 10:45AM CDT
GENFIT: ORGANIZATION OF A WORKSHOP ON GFT505 DURING THE ANNUAL EASL CONGRESS
GENFIT: MINUTES OF THE COMBINED SHAREHOLDERS' MEETING OF APRIL 2, 2014
Thomson Reuters ONE - Thu Apr 03, 1:30AM CDT
GENFIT: MINUTES OF THE COMBINED SHAREHOLDERS' MEETING OF APRIL 2, 2014
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - End of Forecast Surge in Sales for NASH from 2012-2017
M2 - Thu Mar 27, 4:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/254n52/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update" report to their offering. The authors estimates the 2012 off-label sales for nonalcoholic steatohepatitis (NASH) to be approximately $233m across the US and five major European markets of France, Germany, Italy, Spain, and the UK. By forecast end in 2017, The authors expects sales to grow to about $1.36bn, with a compound annual growth rate (CAGR) of 42.2% across the 6MM. The authors expect the US to claim the most sales, contributing $1.28bn of global sales and a CAGR of 43.8%. Major drivers of growth in the NASH market are attributed to two factors: - The growing rate of obesity and diabetes globally. - The launch of Genfit's GFT505 and Intercept/DSP's obeticholic acid (OCA) in 2017. In OCA's favor, its Phase II/IIb trial was stopped early in January 2014, after a planned interim analysis showed that the primary endpoint of the study had been met. While for GFT505, Genfit is aligning itself to register GFT505 among the first approved therapies for NASH and the company received Fast Track designation for the GFT505 NASH program on February 14, 2014. - The authors expect the US' growth will be due in part to the launch of both of these products, while growth in the 5EU will be predominantly driven by GFT505 during the forecast period. Major barriers to the growth of the NASH market are attributed to: - Slow development of therapies specific for NASH. - Unclear understanding of the pathophysiology of NASH. - Inefficient diagnostic tools for NASH that may lead to delayed diagnosis of NASH. For more information visit http://www.researchandmarkets.com/research/25...ityanalyze About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven
M2 - Mon Mar 24, 4:30AM CDT
Summary
GENFIT: GFT505 Eliminates NASH and Fibrosis in a Clinically Relevant Disease Model
Business Wire - Wed Mar 19, 11:45AM CDT
GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new data from Professor Isabelle Leclercq of Universite Catholique de Louvain (Belgium) demonstrating the curative effects of GFT505 in an experimental model of NASH associated with metabolic disorders.
GENFIT TO HOLD A COMBINED GENERAL SHAREHOLDERS' MEETING ON APRIL 2, 2014
Thomson Reuters ONE - Wed Feb 26, 10:45AM CST
GENFIT TO HOLD A COMBINED GENERAL SHAREHOLDERS' MEETING ON APRIL 2, 2014
Cardiovascular Inflammation - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/n3br3p/cardiovascular) has announced the addition of the "Cardiovascular Inflammation - Pipeline Review, H2 2013" report to their offering. 'Cardiovascular Inflammation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cardiovascular Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiovascular Inflammation. Scope - A snapshot of the global therapeutic scenario for Cardiovascular Inflammation. - A review of the Cardiovascular Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cardiovascular Inflammation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cardiovascular Inflammation Overview Therapeutics Development Pipeline Products for Cardiovascular Inflammation - Overview Pipeline Products for Cardiovascular Inflammation - Comparative Analysis Cardiovascular Inflammation - Therapeutics under Development by Companies Cardiovascular Inflammation - Therapeutics under Investigation by Universities/Institutes Cardiovascular Inflammation - Pipeline Products Glance Clinical Stage Products Early Stage Products Cardiovascular Inflammation - Products under Development by Companies Cardiovascular Inflammation - Products under Investigation by Universities/Institutes Cardiovascular Inflammation - Companies Involved in Therapeutics Development Cardiovascular Inflammation - Therapeutics Assessment Drug Profiles trehalose - Drug Profile DMI-4983 - Drug Profile Drug For Inflammation In Ischemia Reperfusion Injury - Drug Profile SAVX-1 - Drug Profile FP-1115 - Drug Profile Cardiovascular Inflammation - Dormant Projects Cardiovascular Inflammation - Discontinued Products Appendix Companies Mentioned Genfit SA Priaxon AG Ampio Pharmaceuticals, Inc. NovelMed Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/n3...iovascular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets: 2013 Report on the International Nonalcoholic Steatohepatitis (NASH) Market - Opportunity Analysis and Forecasts to 2017
Business Wire - Wed Jan 22, 7:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/lmx4bb/opportunityanalyze) has announced the addition of the "2013 Report on the International Nonalcoholic Steatohepatitis (NASH) Market - Opportunity Analysis and Forecasts to 2017" report to their offering.
2013 Report on the International Nonalcoholic Steatohepatitis (NASH) Market - Opportunity Analysis and Forecasts to 2017
M2 - Wed Jan 22, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/b3szw2/opportunityanalyze) has announced the addition of the "2013 Report on the International Nonalcoholic Steatohepatitis (NASH) Market - Opportunity Analysis and Forecasts to 2017" report to their offering. The Nonalcoholic Steatohepatitis (NASH) market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfit's PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharma's FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class. Scope - Overview of NASH, including epidemiology, etiology, symptoms, diagnosis, pathology and disease management. - Analysis of the current and future market competition in the global NASH therapeutics market. - Pipeline analysis: comprehensive data split across Phase II/IIb, emerging trends and mechanisms of action under development, including: oral Proliferator Activated Receptor alpha, delta (PPARa,d) agonist, oral Farnesoid X Receptor (FXR) agonist, subcutaneous Lysyl Oxidase-Like 2 (LOXL2) inhibitor and subcutaneous Glucagon-like Peptide-1 (GLP-1) agonist. - Annualized NASH therapeutics market forecast, annual cost of therapy and treatment usage pattern data from 2012-2017. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. - Key topics covered include strategic clinical and commercial benchmarking assessment of the pipeline and standard of care, market outlook, R&D strategies, and unmet needs for the NASH therapeutics market. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Opportunity Analysis 7 R&D Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/b3...ityanalyze
Global Non-Alcoholic Steatohepatitis Clinical Trials Report - H2, 2013
M2 - Mon Jan 13, 10:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kv3lxq/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials - CATALYSIS, S.L. - Galmed International Ltd. - Genextra S.p.a. - Genfit SA - Gilead Sciences, Inc. - GlaxoSmithKline plc - Immuron Limited - LG Corp. - Phenex Pharmaceuticals AG - Raptor Pharmaceuticals Corp. Clinical Trial Overview of Top Institutes / Government - The National Institute of Diabetes and Digestive and Kidney Diseases - Tehran University of Medical Sciences - Yokohama City University - University of California, San Diego - Mayo Clinic - U.S. Department of Veterans Affairs - Hadassah Medical Organization - University of Michigan - The University of Texas Health Science Center at San Antonio - Imperial College London For more information visit http://www.researchandmarkets.com/research/kv...nalcoholic
GENFIT : HALF-YEAR REPORT ON GENFIT'S LIQUIDITY CONTRACT WITH CM-CIC SECURITIES
Thomson Reuters ONE - Mon Jan 06, 10:45AM CST
HALF-YEAR REPORT ON GENFIT'S LIQUIDITY CONTRACT WITH CM-CIC SECURITIES
Form 4: Update Filing for GP Strategies Corp (GPX)
Vickers Stock Research - Fri Jan 03, 6:08AM CST
GENFIT: IMPLEMENTATION OF THE FIRST INSTALLMENT (EUR1 M) OF A RESERVED CONVERTIBLE BOND LOAN AGREEMENT OF EUR8 M
GENFIT : PATIENT SELECTION FOR THE PHASE IIB STUDY IS SUCCESSFULLY COMPLETED
Thomson Reuters ONE - Fri Nov 22, 1:30AM CST
GFT505: PATIENT SELECTION FOR THE PHASE IIB STUDY IS SUCCESSFULLY COMPLETED
Liver Fibrosis Drug Pipeline Report, H2 2013 Review
M2 - Thu Nov 07, 8:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/r8p9h2/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Liver Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Liver Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Fibrosis. Scope - A snapshot of the global therapeutic scenario for Liver Fibrosis. - A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Liver Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Genzyme Corporation - Gilead Sciences, Inc. - Bioneer Corporation - ViaCord - FibroGen, Inc. - Silence Therapeutics plc. - Genfit - Pharmaxis Ltd. - La Jolla Pharmaceutical Company - LG Life Sciences, Ltd - Digna Biotech, S.L. - Promedior, Inc. - GenKyoTex S.A. - Angion Biomedica Corp. - Virobay Inc. - Intercept Pharmaceuticals, Inc. - GNI, LTD. - Promethera Biosciences - BiOrion Technologies B.V. - ACROVIS biostructures GmbH For more information visit http://www.researchandmarkets.com/research/r8...r_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GENFIT : GFT505: THE DSMB APPROVES THE CONTINUATION OF THE PHASE IIB STUDY IN NASH
Thomson Reuters ONE - Fri Oct 25, 11:30AM CDT
GFT505: THE DSMB APPROVES THE CONTINUATION OF THE PHASE IIB STUDY IN NASH
GENFIT : HALF-YEAR RESULTS FOR 2013
Thomson Reuters ONE - Fri Oct 25, 11:20AM CDT
GENFIT: HALF-YEAR RESULTS FOR 2013
Dyslipidemia - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pl2876/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2013" report to their offering. 'Dyslipidemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dyslipidemia. Scope - A snapshot of the global therapeutic scenario for Dyslipidemia. - A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dyslipidemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Amgen Inc. Sanofi-Aventis Eli Lilly and Company Daiichi Sankyo Company, Ltd Merck & Co., Inc. Euroscreen S.A. Teijin Pharma Limited Novartis AG Biocon Limited Chong Kun Dang Pharmaceutical Dr. Reddy's Laboratories Limited Glenmark Pharmaceuticals Ltd. Kissei Pharmaceutical Co., Ltd. Kowa Company, Ltd. Zydus Cadila Healthcare Limited Bayer AG GW Pharmaceuticals plc Genfit Karo Bio Ligand Pharmaceuticals Incorporated and many more.... For more information visit http://www.researchandmarkets.com/research/pl...slipidemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Atherosclerosis - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n99vdc/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2013" report to their offering. 'Atherosclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Atherosclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Atherosclerosis. Scope - A snapshot of the global therapeutic scenario for Atherosclerosis. - A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Atherosclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Johnson & Johnson AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Isis Pharmaceuticals, Inc. Daiichi Sankyo Company, Ltd Merck & Co., Inc. Novartis AG Dong-A Pharmaceutical Co., Ltd. Dr. Reddy's Laboratories Limited Zydus Cadila Healthcare Limited Bayer AG Genfit PROLOR Biotech, Inc. CSL Limited Yuhan Corporation Anagen Therapeutics, Inc. Cytos Biotechnology AG Pronova BioPharma ASA AFFiRiS AG CIMAB S.A. and many more..... For more information visit http://www.researchandmarkets.com/research/n9...osclerosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GENFIT : THERAPEUTIC POTENTIAL OF GFT505 WIDENED TO NON-HEPATIC FIBROTIC DISEASES; NEW INSIGHTS ON ITS ANTI-FIBROTIC MECHANISM OF ACTION
Thomson Reuters ONE - Mon Apr 14, 1:30AM CDT
GENFIT: THERAPEUTIC POTENTIAL OF GFT505 WIDENED TO NON-HEPATIC FIBROTIC DISEASES; NEW INSIGHTS ON ITS ANTI-FIBROTIC MECHANISM OF ACTION
GENFIT: ORGANIZATION OF A WORKSHOP ON GFT505 DURING THE ANNUAL EASL CONGRESS
Thomson Reuters ONE - Tue Apr 08, 10:45AM CDT
GENFIT: ORGANIZATION OF A WORKSHOP ON GFT505 DURING THE ANNUAL EASL CONGRESS
GENFIT: MINUTES OF THE COMBINED SHAREHOLDERS' MEETING OF APRIL 2, 2014
Thomson Reuters ONE - Thu Apr 03, 1:30AM CDT
GENFIT: MINUTES OF THE COMBINED SHAREHOLDERS' MEETING OF APRIL 2, 2014
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - End of Forecast Surge in Sales for NASH from 2012-2017
M2 - Thu Mar 27, 4:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/254n52/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update" report to their offering. The authors estimates the 2012 off-label sales for nonalcoholic steatohepatitis (NASH) to be approximately $233m across the US and five major European markets of France, Germany, Italy, Spain, and the UK. By forecast end in 2017, The authors expects sales to grow to about $1.36bn, with a compound annual growth rate (CAGR) of 42.2% across the 6MM. The authors expect the US to claim the most sales, contributing $1.28bn of global sales and a CAGR of 43.8%. Major drivers of growth in the NASH market are attributed to two factors: - The growing rate of obesity and diabetes globally. - The launch of Genfit's GFT505 and Intercept/DSP's obeticholic acid (OCA) in 2017. In OCA's favor, its Phase II/IIb trial was stopped early in January 2014, after a planned interim analysis showed that the primary endpoint of the study had been met. While for GFT505, Genfit is aligning itself to register GFT505 among the first approved therapies for NASH and the company received Fast Track designation for the GFT505 NASH program on February 14, 2014. - The authors expect the US' growth will be due in part to the launch of both of these products, while growth in the 5EU will be predominantly driven by GFT505 during the forecast period. Major barriers to the growth of the NASH market are attributed to: - Slow development of therapies specific for NASH. - Unclear understanding of the pathophysiology of NASH. - Inefficient diagnostic tools for NASH that may lead to delayed diagnosis of NASH. For more information visit http://www.researchandmarkets.com/research/25...ityanalyze About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven
M2 - Mon Mar 24, 4:30AM CDT
Summary
GENFIT: GFT505 Eliminates NASH and Fibrosis in a Clinically Relevant Disease Model
Business Wire - Wed Mar 19, 11:45AM CDT
GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new data from Professor Isabelle Leclercq of Universite Catholique de Louvain (Belgium) demonstrating the curative effects of GFT505 in an experimental model of NASH associated with metabolic disorders.
GENFIT TO HOLD A COMBINED GENERAL SHAREHOLDERS' MEETING ON APRIL 2, 2014
Thomson Reuters ONE - Wed Feb 26, 10:45AM CST
GENFIT TO HOLD A COMBINED GENERAL SHAREHOLDERS' MEETING ON APRIL 2, 2014
Cardiovascular Inflammation - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/n3br3p/cardiovascular) has announced the addition of the "Cardiovascular Inflammation - Pipeline Review, H2 2013" report to their offering. 'Cardiovascular Inflammation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cardiovascular Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiovascular Inflammation. Scope - A snapshot of the global therapeutic scenario for Cardiovascular Inflammation. - A review of the Cardiovascular Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cardiovascular Inflammation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cardiovascular Inflammation Overview Therapeutics Development Pipeline Products for Cardiovascular Inflammation - Overview Pipeline Products for Cardiovascular Inflammation - Comparative Analysis Cardiovascular Inflammation - Therapeutics under Development by Companies Cardiovascular Inflammation - Therapeutics under Investigation by Universities/Institutes Cardiovascular Inflammation - Pipeline Products Glance Clinical Stage Products Early Stage Products Cardiovascular Inflammation - Products under Development by Companies Cardiovascular Inflammation - Products under Investigation by Universities/Institutes Cardiovascular Inflammation - Companies Involved in Therapeutics Development Cardiovascular Inflammation - Therapeutics Assessment Drug Profiles trehalose - Drug Profile DMI-4983 - Drug Profile Drug For Inflammation In Ischemia Reperfusion Injury - Drug Profile SAVX-1 - Drug Profile FP-1115 - Drug Profile Cardiovascular Inflammation - Dormant Projects Cardiovascular Inflammation - Discontinued Products Appendix Companies Mentioned Genfit SA Priaxon AG Ampio Pharmaceuticals, Inc. NovelMed Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/n3...iovascular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets: 2013 Report on the International Nonalcoholic Steatohepatitis (NASH) Market - Opportunity Analysis and Forecasts to 2017
Business Wire - Wed Jan 22, 7:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/lmx4bb/opportunityanalyze) has announced the addition of the "2013 Report on the International Nonalcoholic Steatohepatitis (NASH) Market - Opportunity Analysis and Forecasts to 2017" report to their offering.
2013 Report on the International Nonalcoholic Steatohepatitis (NASH) Market - Opportunity Analysis and Forecasts to 2017
M2 - Wed Jan 22, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/b3szw2/opportunityanalyze) has announced the addition of the "2013 Report on the International Nonalcoholic Steatohepatitis (NASH) Market - Opportunity Analysis and Forecasts to 2017" report to their offering. The Nonalcoholic Steatohepatitis (NASH) market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfit's PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharma's FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class. Scope - Overview of NASH, including epidemiology, etiology, symptoms, diagnosis, pathology and disease management. - Analysis of the current and future market competition in the global NASH therapeutics market. - Pipeline analysis: comprehensive data split across Phase II/IIb, emerging trends and mechanisms of action under development, including: oral Proliferator Activated Receptor alpha, delta (PPARa,d) agonist, oral Farnesoid X Receptor (FXR) agonist, subcutaneous Lysyl Oxidase-Like 2 (LOXL2) inhibitor and subcutaneous Glucagon-like Peptide-1 (GLP-1) agonist. - Annualized NASH therapeutics market forecast, annual cost of therapy and treatment usage pattern data from 2012-2017. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. - Key topics covered include strategic clinical and commercial benchmarking assessment of the pipeline and standard of care, market outlook, R&D strategies, and unmet needs for the NASH therapeutics market. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Opportunity Analysis 7 R&D Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/b3...ityanalyze
Global Non-Alcoholic Steatohepatitis Clinical Trials Report - H2, 2013
M2 - Mon Jan 13, 10:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kv3lxq/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials - CATALYSIS, S.L. - Galmed International Ltd. - Genextra S.p.a. - Genfit SA - Gilead Sciences, Inc. - GlaxoSmithKline plc - Immuron Limited - LG Corp. - Phenex Pharmaceuticals AG - Raptor Pharmaceuticals Corp. Clinical Trial Overview of Top Institutes / Government - The National Institute of Diabetes and Digestive and Kidney Diseases - Tehran University of Medical Sciences - Yokohama City University - University of California, San Diego - Mayo Clinic - U.S. Department of Veterans Affairs - Hadassah Medical Organization - University of Michigan - The University of Texas Health Science Center at San Antonio - Imperial College London For more information visit http://www.researchandmarkets.com/research/kv...nalcoholic
GENFIT : HALF-YEAR REPORT ON GENFIT'S LIQUIDITY CONTRACT WITH CM-CIC SECURITIES
Thomson Reuters ONE - Mon Jan 06, 10:45AM CST
HALF-YEAR REPORT ON GENFIT'S LIQUIDITY CONTRACT WITH CM-CIC SECURITIES
Form 4: Update Filing for GP Strategies Corp (GPX)
Vickers Stock Research - Fri Jan 03, 6:08AM CST
GENFIT: IMPLEMENTATION OF THE FIRST INSTALLMENT (EUR1 M) OF A RESERVED CONVERTIBLE BOND LOAN AGREEMENT OF EUR8 M
GENFIT : PATIENT SELECTION FOR THE PHASE IIB STUDY IS SUCCESSFULLY COMPLETED
Thomson Reuters ONE - Fri Nov 22, 1:30AM CST
GFT505: PATIENT SELECTION FOR THE PHASE IIB STUDY IS SUCCESSFULLY COMPLETED
Liver Fibrosis Drug Pipeline Report, H2 2013 Review
M2 - Thu Nov 07, 8:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/r8p9h2/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Liver Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Liver Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Fibrosis. Scope - A snapshot of the global therapeutic scenario for Liver Fibrosis. - A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Liver Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Genzyme Corporation - Gilead Sciences, Inc. - Bioneer Corporation - ViaCord - FibroGen, Inc. - Silence Therapeutics plc. - Genfit - Pharmaxis Ltd. - La Jolla Pharmaceutical Company - LG Life Sciences, Ltd - Digna Biotech, S.L. - Promedior, Inc. - GenKyoTex S.A. - Angion Biomedica Corp. - Virobay Inc. - Intercept Pharmaceuticals, Inc. - GNI, LTD. - Promethera Biosciences - BiOrion Technologies B.V. - ACROVIS biostructures GmbH For more information visit http://www.researchandmarkets.com/research/r8...r_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GENFIT : GFT505: THE DSMB APPROVES THE CONTINUATION OF THE PHASE IIB STUDY IN NASH
Thomson Reuters ONE - Fri Oct 25, 11:30AM CDT
GFT505: THE DSMB APPROVES THE CONTINUATION OF THE PHASE IIB STUDY IN NASH
GENFIT : HALF-YEAR RESULTS FOR 2013
Thomson Reuters ONE - Fri Oct 25, 11:20AM CDT
GENFIT: HALF-YEAR RESULTS FOR 2013
Dyslipidemia - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pl2876/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2013" report to their offering. 'Dyslipidemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dyslipidemia. Scope - A snapshot of the global therapeutic scenario for Dyslipidemia. - A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dyslipidemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Amgen Inc. Sanofi-Aventis Eli Lilly and Company Daiichi Sankyo Company, Ltd Merck & Co., Inc. Euroscreen S.A. Teijin Pharma Limited Novartis AG Biocon Limited Chong Kun Dang Pharmaceutical Dr. Reddy's Laboratories Limited Glenmark Pharmaceuticals Ltd. Kissei Pharmaceutical Co., Ltd. Kowa Company, Ltd. Zydus Cadila Healthcare Limited Bayer AG GW Pharmaceuticals plc Genfit Karo Bio Ligand Pharmaceuticals Incorporated and many more.... For more information visit http://www.researchandmarkets.com/research/pl...slipidemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Atherosclerosis - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n99vdc/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2013" report to their offering. 'Atherosclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Atherosclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Atherosclerosis. Scope - A snapshot of the global therapeutic scenario for Atherosclerosis. - A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Atherosclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Johnson & Johnson AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Isis Pharmaceuticals, Inc. Daiichi Sankyo Company, Ltd Merck & Co., Inc. Novartis AG Dong-A Pharmaceutical Co., Ltd. Dr. Reddy's Laboratories Limited Zydus Cadila Healthcare Limited Bayer AG Genfit PROLOR Biotech, Inc. CSL Limited Yuhan Corporation Anagen Therapeutics, Inc. Cytos Biotechnology AG Pronova BioPharma ASA AFFiRiS AG CIMAB S.A. and many more..... For more information visit http://www.researchandmarkets.com/research/n9...osclerosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
